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Abstract: Over the last few years, the application of nanotechnology to nutraceuticals has been 
rapidly growing due to its ability to enhance the bioavailability of the loaded active ingredients, 
resulting in improved therapeutic/nutraceutical outcomes. The focus of this work is nanoprebiotics 
and nanoprobiotics, terms which stand for the loading of a set of compounds (e.g., prebiotics, 
probiotics, and synbiotics) in nanoparticles that work as absorption enhancers in the gastrointestinal 
tract. In this manuscript, the main features of prebiotics and probiotics are highlighted, together 
with the discussion of emerging applications of nanotechnologies in their formulation. Current 
research strategies are also discussed, in particular the promising use of nanofibers for the delivery 
of probiotics. Synbiotic-based nanoparticles represent an innovative trend within this area of 
interest. As only few experimental studies on nanoprebiotics and nanoprobiotics are available in the 
scientific literature, research on this prominent field is needed, covering effectiveness, 
bioavailability, and safety aspects. 
Keywords: nutraceuticals; nanotechnologies; nanonutraceuticals; prebiotics; probiotics; synbiotics. 
 
1. Nanonutraceuticals 
1.1. Nutraceuticals 
Beside the emerging need for natural origin alternatives to pharmaceuticals, the interest is 
focusing more and more on possible applications of food derived products that can be used as tools 
to prevent (and in some cases also cure) or delay the onset of a health issue [1–3]. Nutraceuticals, are 
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a novel toolbox not completely explored so far for its full potential in medicine [4–7]. Nutraceuticals, 
a portmanteau of the words ‘nutrition’ and ‘pharmaceutical’ [2], have been defined as “the 
phytocomplex if they derive from a food of vegetal origin, and as the pool of the secondary 
metabolites if they derive from a food of animal origin, concentrated and administered in the more 
suitable pharmaceutical form” [8]. Examples of substances that have nutritional and nutraceutical 
interest are antioxidants, vitamins, polyunsaturated fatty acids, dietary fibres, prebiotics, and 
probiotics [9]. Nutraceuticals reside nowadays in a gray area between pharmaceuticals and food; 
their safety and efficacy in health conditions and safety must be substantiated by clinical data; 
moreover, there is lack of a shared regulatory system for them [7,10]. 
1.2. From Nanopharmaceuticals to Nanonutraceuticals 
1.2.1. Characteristics of Nanoparticles and General Classification 
Within the different definitions of nanomaterials, these can be described as the products of 
nanotechnology, characterized by at least one dimension within the size range below 100 nanometers 
[11–13]. Due to their remarkable properties and versatility, nanomaterials are being exploited in 
different fields, e.g., agriculture, health, electronics, cosmetics [14–18], representing a great challenge, 
in particular, in food science and technology, environment, and human health [19]. The progress in 
pharmaceutical nanotechnology has led to a new class of products, the so-called 
nanopharmaceuticals [20,21], defined as pharmaceutical drug molecules formulated in nanomaterials 
. Different types of nanoformulations are being exploited for the treatment of neurodegenerative 
diseases, cancer, infectious diseases, and others [22–26]. Besides, nanomaterials are also succeeding 
in offering new advanced tools for imaging and diagnosis [27] which, combined with therapy, have 
been proposed as nanotheranostics. These formulations are also being tailored for personalized 
medicine. 
Nanoparticles can be produced from natural (e.g., proteins, polysaccharides, lipids) and from 
synthetic (e.g., polymers) sources. Ideally, materials should be biocompatible, biodegradable, and 
biotolerable, namely the way by which designed materials are tolerated by the body, and of generally 
recognized as safe (GRAS) status, in order to be used in pharmaceutical and nutraceutical products. 
Among the available options, and if the nanoparticles are intended for oral administration (as 
happens with nanonutraceuticals), lipid nanoparticles are of special interest [28–31]. Lipids are 
known for their role as absorption enhancers in the gut, which contribute to improving the oral 
bioavailability of several drugs and biomolecules. Besides this, the loading of poorly soluble drugs 
into lipid nanoparticles overcome the limitations encountered in their formulation into final 
products. Lipid nanoparticles can be produced from well-known lipids existing both in the human 
body and in foodstuff (e.g., fatty acids, triglycerides, phospholipids, waxes, cholesterol) thereby 
enhancing their biodegradability, and biocompatibility profiles [32].  
Among polysaccharides, chitosan [33–37] and alginate [33,38,39], have been frequently used in 
the production of nanoparticles for oral delivery. Being a mucoadhesive polysaccharide, chitosan is 
able to increase cellular permeability and improves the bioavailability of orally administered drugs 
and proteins. Moreover, the molecule itself exhibits antimicrobial properties, and has a low toxicity. 
The molecule has chemical functional groups that can be modified for site specific targeting. Alginate 
is also a versatile mucoadhesive natural polymer with very low toxicity in vivo. Alginate 
nanoparticles have a hydrophilic character with improved loading capacity for hydrophilic drugs, 
being able to modify their release profile. Alginate nanoparticles are reported as adjuvants in 
vaccinations and can be produced conjugated with dextran to modify the release profile of proteins 
and other macromolecules intended for oral administration [40]. 
Nanopharmaceuticals and nanonutraceuticals are obtained, respectively, when a 
pharmaceutical or a nutraceutical is formulated in nanoparticles. The rationale for their development 
is mainly addressed to improve the physicochemical properties (e.g., solubility) and pharmacokinetic 
parameters (tmax, Cmax, area under the plasma drug concentration–time curve (AUC)), with the 
ultimate aim to reduce the dose required to observe the therapeutic/nutraceutical outcome and thus 
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the possible risk of toxicity [41–43]. Parameters, such as efficiency, quality, and safety should 
therefore be considered. Nevertheless, regulatory issues related to nanopharmaceuticals still need 
further developments [44].  
1.2.2. Emerging Area of Applications 
Nanopharmaceuticals and the great change of the pharmaceutical industry have a great impact 
also on nutraceuticals. The recent work of Agarwal et al. [45] gives the patented and approval 
scenario of nanopharmaceuticals with regards to biomedical application, manufacturing procedure, 
and safety aspects. 
Wu et al. [46] highlighted how nanotherapeutics and nanopharmaceuticals could lead to a more 
precise individual diagnosis, improve targeted therapies, reduce side effects, and enhance 
therapeutic monitoring. The same review also underlines that the field of nanomedicine is at its early 
stage and that further efforts to translate their potential into clinical trials and medical practice are 
still needed. 
A growing number of studies are addressed towards the application of nanotechnologies to 
nutraceuticals [47–50] in order to obtain improved bioavailability, delivery, and effect. This leads to 
the development of an emerging area of innovative products: the nanonutraceuticals [51–53]. 
Nanotechnology can be used to improve absorption, bioavailability, stability, and controlled 
release of nutrients and nutraceuticals, thereby increasing health benefits; some examples of potential 
advantages of applications of nanotechnology on the nutraceuticals are (i) efficient encapsulation; (ii) 
smart delivery and release from a nanoformulation. For example, research on encapsulation of 
nutraceuticals into biodegradable, environmentally friendly nanocarriers, is ongoing to increase their 
absorption and their therapeutic potential. 
The nanonutraceutical formulations represent a valuable and promising strategy to maintain 
nutraceutical health beneficial properties at a nano level, to guarantee safety and efficacy, when used 
in managing health conditions, particularly for patients who are not eligible for a conventional 
pharmacological therapy. Follow-up studies, as reported by recent works [54–57], and 
communication strategies [58], are needed for both the nanopharmaceuticals and nanonutraceuticals 
[59,60], in view of expanding the area of interest to different health conditions. For instance, Aditya 
et al. [61] describe the current status of the various delivery systems that are used for the delivery of 
hydrophilic bioactive compounds and discuss future prospects to be explored for the delivery of 
hydrophilic bioactive compoundse.g., niosomes, bilosomes, cubosomes. 
2. Focus on Nanotechnologies Applied to Prebiotics, Probiotics, and Synbiotics 
Focus of this perspective is the application of nanotechnologies to food supplements containing 
prebiotics, probiotics, and synbiotics. This section consists of (i) shot on prebiotics, probiotics, and 
synbiotics; (ii) definition and delineation of nano-prebiotics, nano-probiotics, and nano-synbiotics. 
2.1. An Overview on Prebiotics, Probiotics, and Synbiotics 
2.1.1. Prebiotics  
Prebiotics [62–66] are a special form of dietary fiber with health benefits, which invoke 
alterations in the host microbial ecosystem, not only in the gut, via their selective administration by 
live host microbes [67]. Food ingredients like prebiotics are classified on the basis of some principles, 
such as resistance to digestion in upper alimentary tract, selective stimulation of probiotic growth, 
beneficial health effects in the host, stability in different conditions of food/feed processing, and 
fermentation process through intestinal microbiota. They are found in various sources, including 
some non-digestible oligosaccharides, non-digestible carbohydrates, yacon, unrefined wheat, 
unrefined barley, soybeans, raw oats, breast milk, and inulin sources (e.g., chicory roots and 
Jerusalem artichoke) [68]. Some compounds found in prebiotics are soya-oligosaccharide, xylo-
oligosaccharide, pyrodextrins, gluco-oligosaccharide, lactulose, malto-oligosaccharide, galactans 
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(galacto-oligosaccharide (GOS)), oligofructose, isomalto-oligosaccharide (IOS), fructans (FOS and 
inulin), mannan-oligosaccharide (MOS), lactitol, and non-starch polysaccharides (NSP). Figure 1 
gives an overview of prebiotics. 
 
Figure 1. Overview of prebiotics. 
Several mechanisms are involved in the bioactivity of prebiotics and probiotics [69,70], as 
described in Figure 2.  
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Figure 2. Overview of mechanism of action of pre and probiotics. 
The metabolic products of such microorganisms can drop the gastrointestinal (GI) pH by 
carbohydrate fermentation via Bifidobacteria and Lactobacillus thereby influencing mineral uptake, 
growth, and spread of gut microbiota, epithelial integrity, and hormonal regulation. They also are 
able to enhance the absorption of trace elements and especially of iron and act on the regulation of 
body immune function. The prebiotics can use the short-chain fatty acids (SCFAs) as an energy 
source. 
2.1.2. Probiotics  
The FAO (Food and Agriculture Organization) and WHO (World Health Organization) have 
defined probiotics as non-pathogenic living microorganisms that ensure host health if used properly 
in foods or as dietary supplements [71,72]. Probiotics come from different sources, such as various 
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natural environments, human gut microbiota, and foods. The main properties of probiotics like the 
ability to survive through the gastrointestinal tract, the resistance against bile and gastric acidity, and 
the stimulation of the activity of bile salt hydrolase, promote health benefits to the host [68,73–81]. 
The count of probiotic bacteria (colony-forming units (CFU)/g) in probiotic-containing products 
differ among the countries; for example, 107 CFU/g in the USA and 109 CFU/g in Canada. The effective 
dose generally contains >106-108 CFU/g or >108-1010 CFU/d of live probiotic bacteria [82,83]. Most 
probiotics are found in Gram-positive bacteria, including Streptococcus, Bacillus, Lactobacillus, 
Enterococcus, and Pediococcus. The probiotics can also include fungal and yeast species such as 
Saccharomyces cerevisiae and Kluyveromyces. Only some microorganisms such as Lactobacillus spp., 
Bifidobacterium spp., and Lactococcus are known as generally recognized as safe (GRAS) despite the 
existence of diverse microorganisms which can act as probiotics with health benefits [84–86]. Figure 
3 gives an overview of probiotics. 
 
Figure 3. An overview of probiotics. 
The reported key mechanisms of action of probiotics [87] have been mentioned as follows (see 
Figure 2): enhancement of epithelial barrier, modulation of insulin-sensitive tissues, synthesis of 
antimicrobial substances, multi-pathogen competition, and induction of mucin secretion. The 
probiotics are able to adhere to epithelium, resulting in microbial elimination. They also modulate 
the immune function via the stimulation of signaling pathways to upregulate anti-inflammatory 
cytokines and growth factors, to differentiate T-regulatory cells (Tregs), and to interact with the gut-
brain axis (GBA) by endocrine regulation and neurologic functions. 
2.1.3. Synbiotics  
The synbiotic agents are a combination of prebiotics and probiotics with beneficial effects on 
host through the enhancement of activity and survival of beneficial microorganisms in the 
gastrointestinal tract, so that they can selectively provoke the growth and stimulate the metabolism 
of one or more health-promoting bacteria, thereby enhancing the host welfare [88–97]. The most 
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important issue in the design of synbiotics resides in the prebiotic and probiotic selection criteria and 
requirements, which should be clearly described.  
2.1.4. Health Promoting Effect of Prebiotics, Probiotics, and Synbiotics 
The International Scientific Association for Probiotics and Prebiotics (ISAPP) introduced a wide 
range of products containing the probiotics with health promoting effects, including non-edible 
products (e.g., vaginal preparations), baby formulas (e.g., first milk), drugs, therapeutic supplements 
(e.g., for enteral nutrition), and foods (e.g., fermented milk with reportedly health beneficial effects) 
[98]. 
Some of the reported beneficial effects of probiotics in human health include anticancer [99–111], 
anti-allergic [112,113], anti-diabetic [114–116], anti-obesity [117–120], anti-pathogenic [121,122], 
immunomodulatory [123], and anti-inflammatory [124–127] activities [128], as reported in Table 1. In 
an in vitro study, Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS) as a 
quantitative analysis technique was applied to evaluate the proteomic profile of colon cancer cells in 
Lactobacillus kefiri SGL 13, and the results indicated antiproliferative and pro-apoptotic activities for 
this strain on human colon adenocarcinoma cell line HT29 [99]. In another study, the airway hyper 
reactivity was suppressed in ovalbumin-sensitized samples by Lactobacillus spp. (such as Lactobacillus 
and Pediococcus) via a reduction in the level of Th2 cytokines, OVA-specific IgE and IgG1 as well as 
an increase in the level of IgG2a [112]. Lactobacillus fermentum cell-free supernatant (LCFS) caused 
cancer cell death in 3D HCT-116 conditions through the induction of apoptosis in the colon cancer 
cell line and the antiproliferative activity by the inhibition of NF-κB signaling [129]. The use of 
lactoferrin and Bifidobacterium longum BB536 managed the enteropathy caused by diclofenac in rat 
samples by modulating the proinflammatory pathway of TLR-2/-4/NF-kB [130]. Othman et al. [131], 
studied the effect of inactivated Bifidobacterium longum intake on obese diabetes affected mice. They 
reported a   significant decrease of body weight gain, adipose tissue mass and blood glucose levels, 
as well as a significant reduction in blood glucose after a 5 weeks treatment. The treatment also 
resulted in  reduced levels of cholesterol and triglycerides [131]. 
The administration of three strains of Bifidobacteria in the adult rats improved neuronal plasticity 
and cognitive behavior [132].  
Prebiotics have been reported to have different activities; for example, generation of bacteriocins, 
maintenance of gut health [133], possibility to be used as food additive and starter culture, clearance 
of cholesterol [134,135], potentiation of immune defense [136], inhibition of constipation and risk of 
obesity [137,138], inhibition of colitis [139], protection of colon and other organs against cancer [140–
142], reduction of cardiovascular disease risk factors, antioxidant activity [143,244], over-
bioavailability [145]. According to scientific published data, the administration of oligofructose-
enriched inulin (OEI) promotes malondialdehyde content, lipid profile, glycemic indices, and 
antioxidant level in female patients suffering from type II diabetes [146]. The supplementation of 
inulin in shaken cultures was found to increase the growth rate of L. plantarum ST16 [147]. Based on 
the findings from Ramos et al. [148], the administration of fructooligosaccharides (FOS) was tolerated 
and decreased the total and free p-cresyl sulfate (PCS) in the serum samples of patients with non-
diabetic chronic kidney disease (NDD-CKD). 
The therapeutic potential of synbiotics has been comprehensively discussed in a recent review 
published by Flesch et al. [149]. According to their findings, the patients with irritable bowel 
syndrome (IBS) when receiving B. longum BB536 and L. rhamnosus HN001 plus vitamin B6 showed 
restoration of intestinal permeability and gut microbiota, as well as amelioration of the disease 
symptoms [150]. In the research of Mohan et al., the synbiotic AMFTM 15+ manuka honey yogurt 
showed antibacterial properties, followed by increasing probiotic bacteria and producing lactic and 
propionic acids [151]. A study reported gut health enhancement following the administration of 
seaweed-based synbiotic of Gracilaria coronopifolia which caused the reduction of inflammation, the 
generation of reactive oxygen species (ROS), and diminution of the oxidative stress-induced cell 
damage [152]. According to Sarwar et al., the textural properties, such as adhesiveness, cohesiveness, 
and hardness, were enhanced following the co-administration of inulin and Saccharomyces boulardii 
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[153]. In Table 1 an updated overview of in vitro and in vivo studies on prebiotic, probiotic, and 
synbiotic products is given. 
Table 1. An updated overview of in vitro and in vivo studies on prebiotic, probiotic, and synbiotic 
products. 
Type 
Microorganisms/
Prebiotics 
Activity Study References 
Probiotic Bacillus and 
Enterobacter 
Anticancer and 
antioxidant 
effect 
The intracellular cell-free supernatants (CFS) 
from Bacillus licheniformis KT921419 and the 
ethyl acetate extracts could control the growth of 
HT-29, a colon cancer cell line 
[100] 
L. plantarum C70 Anticancer effect L. plantarum C70 by releasing the 
exopolysaccharide caused 73.1% and 88.1% 
cytotoxic properties against the breast and colon 
cancers, respectively   
[101] 
Kluyveromyces 
marxianus and 
Pichia kudriavzevii 
Anticancer effect According to analysis of Annexin V/PI and 
DAPI, an apoptotic induction was observed due 
to exopolysaccharides released by probiotic 
yeasts of Kluyveromyces marxianus and Pichia 
kudriavzevii 
[102] 
Lactobacilli cocktail Anticancer effect HT-29, a human colorectal carcinoma cell line 
was controlled by Lactobacilli cocktail via the 
modulation of the Notch and Wnt/β-catenin 
signaling pathways 
[104] 
L. rhamnosus Anticancer effect The bioconversion of cranberry 
proanthocyanidins to Lactobacillus rhamnosus 
could result in the IC50 values of 20.1 and 47.8 
μg/mL 
[105] 
Bifidobacterium 
infantis, L. 
acidophilus, 
Enterococcus 
faecalis, Bacillus 
cereus 
Anti-
inflammatory 
effect 
A mixture of aerobic probiotics improved the 
functions of various intestinal barriers and the 
restoration of lucrative intestinal microbiota in 
the mouse model of DSS-induced chronic colitis, 
meaning anti-inflammatory properties  
[127] 
Saccharomyces 
boulardii CNCM I-
745 
Anti-
inflammatory 
effect 
The inflammatory response was modulated in 
mucositis caused by 5-FU (fluorouracil) via the 
probiotic Saccharomyces boulardii CNCM I-745 
[103] 
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through the control of TLR 2 and 4 as well as the 
reduction of pro-inflammatory and NF-κB 
cytokines 
L. casei 
IMAU60214 
Immunomodula
tory effect 
The use of L. casei IMAU60214 killed by heat 
increased the activity of M1-like pro-
inflammatory phenotype through the TLR2 
signaling pathway 
[123] 
L. plantarum Antimicrobial 
effect 
L. plantarum ZLP001 impeded the ETEC 
adhesion and linked with IPEC-J2 cells via the 
competition and exclusion 
[122] 
Lactobacillus Anti-diabetic 
effect 
The lactobacillus strain alleviated the levels of 
blood sugar and HbA1c in diabetic rats 
[115] 
L. plantarum 
LMT1-48 
Anti-obesity 
effect 
The body weight and abdominal fat content 
were decreased in mouse models fed a modified 
diet through the administration of L. plantarum 
LMT1-48 at a density of 106 CFU/mL 
[117] 
Hafnia alvei Anti-obesity 
effect 
Fat mass, food intake, and body weights were 
reduced in the mouse model of obesity and 
hyperphagia 
[118] 
Eurotium cristatum Anti-obesity 
effect 
The administration of Eurotium cristatum 
showed anti-obesity activity in mice fed a high-
fat diet (HFD) through the modulation of gut 
microbiota 
[119] 
L. plantarum strain 
TCI378 
Anti-obesity The expression of glucose transporter type 4 
(GLUT-4) and adipocyte-specific genes perilipin 
1 was suppressed by metabolism derivatives 
from L. plantarum strain TCI378 
[120] 
Prebiotic Galacto-
oligosaccharides 
and phycocyanin 
Anticancer effect The prebiotics co-administered by phycocyanin 
arrested the cell cycle at the G0/G1 phase, 
resulting in inhibited growth of HCT116 cells 
[141] 
Chondroitin 
Sulfate 
Disaccharide 
Anticancer effect The growth of HT-29, human colon cancer cell 
line, was controlled by Chondroitin sulfate (CS)-
Keel disaccharide (CSD) generated by 
chondroitin AC lyase, estimating at 80% 
antiproliferative activity 
[140] 
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Short-chain fatty 
acids 
Antiproliferativ
e effects 
The administration of short-chain fatty acids 
(SCFAs) prevented the expression of genes 
involved in human colorectal cancer cells 
[142] 
Blueberry 
anthocyanins 
Antioxidant 
effect 
The density and composition of intestinal 
microbiota in human models were increased by 
consumption of high purity blueberry 
anthocyanins through the increase in the 
modulatory and prebiotic activities 
[143] 
Oligosaccharides Antioxidant 
effect 
The water-soluble oligosaccharide of EMOS-1a 
showed 1420% proliferation level 
[144] 
Lycium barbarum 
polysaccharide 
Immunomodula
tion 
effect 
The administration of polysaccharides derived 
from Lycium barbarum in mice showed 
immunomodulatory effects, and enhanced 
density of beneficial bacteria and gut microbiota 
[136] 
Synbiotic Djulis 
(Chenopodium 
formosanum) with 
L. acidophilus 
Anticancer effect The co-administration of Djulis (Chenopodium 
formosanum Koidz.) and Lactobacillus acidophilus 
inhibited the growth of rat colon cancer cells 
through the promotion of apoptosis, 
proliferation, and inflammation 
[80] 
L. casei, 
acidophilus, 
rhamnosus, 
bulgaricus, 
Bifidobacterium 
breve, longum and 
Streptococcus 
thermophilus with 
fructo-
oligosaccharides. 
Anticancer and 
antioxidant 
effect 
Ten weeks of low-calorie diet program along 
with synbiotic supplementation enhanced the 
activity of superoxide dismutase (SOD) and 
reduced the serum level of malondialdehyde 
(MDA) in obese patients suffering from breast 
cancer-related lymphedema 
[89] 
Weissella cibaria 
FB069 with 
xylooligosacchari
des 
Anticancer effect The use of synbiotic-fermented soymilk 
(containing xylooligosaccharides and Weissella 
cibaria FB069) inhibited the proliferation of 
HCT116 and Caco-2, colorectal cancer cell lines, 
through the reduction in the transcription of 
MD2/TLR4/MyD88/NF-κB   
[90] 
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Auricularia 
auricula aqueous 
with L. acidophilus 
La-5 and 
Bifidobacterium 
bifidum Bb-12 
Antioxidant 
effect 
The aqueous extract of Auricularia auricula in the 
presence of L. acidophilus La-5 and 
Bifidobacterium bifidum Bb-12 significantly 
elevated the level of phenolic compounds and 
the activity of antioxidant properties up to 
1057.6 mg of Gallic acid/kg and 115.30 of mg 
BHT eq/kg following 28-day storage 
[91] 
L. bulgaricus PXN 
39, L. casei subsp. 
casei PXN 37, 
Bifidobacterium 
breve PXN 25, L. 
rhamnosus PXN 
54, B. infantis PXN 
27 Lactobacillus 
acidophilus PXN 
35, Streptococcus 
thermophilus PXN 
66 with fructo-
oligosaccharides 
Immunomodula
tion 
effect 
The use of multispecies symbiotic showed 
immunoregulatory effects on the expression 
levels of CD4 and IgA in mice exposed to 
lipopolysaccharide (LPS) 
[92] 
L. plantarum with 
inulin 
Neuropsycholog
ical effect 
Concomitant administration of inulin and L. 
plantarum in diabetic rats improved 
CREB/BDNF/TrkB signaling pathway, serotonin 
secretion, brain parameters, intestinal microbial 
composition, and oxidative stress, thus leading 
to improved memory and learning disorders 
[93] 
β-glucan, Bacillus 
coagulans, and 
inulin, lactic acid 
Anti-diabetic 
effect 
Eight weeks of taking daily synbiotic plus lactic 
acid improved the levels of GSH-Px, SOD and 
HbA1c in patients with type II diabetes 
[94] 
Corn starch, 
maltodextrin, 
inulin, 
fructooligosacchar
ides, potassium 
chloride, 
magnesium 
sulfate, mangan 
sulfate with L. 
Improve 
symptoms of 
diarrhea-
predominant 
irritable bowel 
syndrome 
Irritable bowel syndrome (IBS) symptoms were 
improved by synbiotic treatment through an 
increase in fecal acetate and butyrate, colonic 
CD4+ T cells, mucosal microbial diversity as 
well as a decrease in surrogate of intestinal 
barrier function and fecal zonulin 
[95] 
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casei W56, 
acidophilus W22, 
paracasei W20, 
salivarius W24, 
plantarum W62, 
Lactococcus lactis 
W19, 
Bifidobacterium 
lactis W51 and 
W52, and 
Bifidobacterium 
bifidum W23 
Grape pomace 
extract with 
lactobacilli 
Anti- 
inflammatory 
effect 
The co-administration of lactobacilli and 
prebiotic grape pomace caused a 
downregulation of inflammatory genes, 
proteins, signaling molecules through the 
symbiotic effects 
[96] 
L. acidophilus, L. 
rhamnosus, B. 
longum and 
Bifidobacterium 
bifidum, 
Saccharomyces 
boulardii with 
fructo-
oligosaccharides 
Hepatoprotectiv
e effects 
The administration of synbiotic soy yogurt 
controlled hypercholesterolemia in mice liver by 
reducing the levels of low-density lipoprotein 
cholesterol, triacylglycerols, blood cholesterol, 
and lipid peroxidation. 
[97] 
2.2. Nano-Prebiotics, Nano-Probiotics, and Nano-Synbiotics 
Recently, emerging applications of nanotechnologies in prebiotics and probiotics have been 
developed and carried out as reported in Table 2 [154–167].  
Table 2. Emerging applications of nanotechnologies on nanoprobiotics, nanoprebiotics, and nano 
synbiotics. 
Type Activity Study References 
Probiotic Antimicrobial 
effect 
The polylysine-induced poly glutamic acid (PG) films caused 
protection of probiotics against food-borne pathogens 
[154] 
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Anticancer effect The high levels of synthesized silver/Lactobacillus rhamnosus 
GG nanoparticles (Ag-LNPs) led to a decline in the rate of HT-
29 live cells 
[155] 
Anticancer and 
antimicrobial 
effect 
The fabrication of copper oxide nanoparticles (CuO-NPs) 
using L. casei could control the proliferation of HT-29, a 
human colon carcinoma cell line, and human gastric 
carcinoma cell line, as well as could eliminate Pseudomonas 
aeruginosa and Staphylococcus aureus 
[156] 
Anticancer and 
antioxidant 
effect 
The L. casei capped-SeNPS suppressed the cytotoxicity caused 
by Diquat and oxidative damage, impeded the cell damage 
and apoptosis induced by H2O2, and induced the apoptosis 
mediated by the HepG2 cell line 
[157] 
Anticancer and 
antioxidant 
effect 
The findings from the administration of L. casei 393-SeNPs 
were the induction of HepG2 cell line apoptosis, the elevation 
of oxidative damage caused by Diquat in IECs, and the 
reduction in gut barrier dysfunction caused by ETEC K88 via 
the antioxidant functions, the regulation of inflammation, the 
establishment of gut epithelial barrier integrity, and the 
balance of gut microflora 
[158] 
Anticancer effect Dead nano-scale L. plantarum could impede the proliferation 
of a colorectal cancer cell line through an increase in the 
expression level of IgA, an induction of cancer cell cycle arrest 
and apoptosis, and a suppression of inflammatory response 
[159] 
Anticancer and 
antioxidant 
effect 
The synthesis gold nanoparticles (AuNps) having antioxidant 
activity and low cytotoxicity using L. kimchicus DCY51T strain 
exhibited the activity of a protective protein capping layer 
[160] 
Prebiotic 
 
Improve drug 
delivery 
High molecular weight (HMW) inulin nanoparticles were 
fabricated to achieve drug delivery system, whose 
concentration of <200μg/mL had no toxicity for peripheral 
blood mononuclear cells (PBMCs) 
[161] 
Antimicrobial 
effect 
The probiotics were internalized by phthalyl dextran 
nanoparticles (PDNs) to construct pediocin, aiming at the 
alteration of gut microbiome composition, the suppression of 
pathogenic intestinal infections, and the elevation of beneficial 
bacteria species 
[162] 
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Antimicrobial 
effect 
The higher pediocin generation following the administration 
of PIN-internalized probiotics with 0.171 polydispersity index 
(PDI) with a size of about 203 nm showed the maximum 
antimicrobial properties 
[163] 
Synbiotic 
 
Antimicrobial 
effect 
The activity of Listeria monocytogenes and Escherichia coli K99 
was inhibited by L. plantarum exposed to phthalylpullulan 
nanoparticle (PPN) due to production of antimicrobial 
peptides via intracellular stimulation 
[164] 
The photo 
protective effect 
A cream containing L. rhamnosus plus Selenium nanoparticles 
could heal the side effects induced by sunburn and showed 
sun protection factor (SPF) of 29.77 in Wistar rat model 
[165] 
Improve 
delivery system 
A new formulation of nano-emulsion containing E. faecium 
plus inulin could increase probiotic bacterial viability and 
stability 
[166] 
Improve 
tolerance of 
probiotic 
bacteria 
Beads reinforced by inulin (5% w/v) had the highest effect on 
bacterial protection against bile salts 
[167] 
Caneus et al. [168] remarked how nanomedicine, together with the known practices of 
prebiotics, probiotics, and synbiotics, represents a valuable approach in creating an optimal 
environment within the gastrointestinal tract.  
Exploring the nanonization strategies of probiotics and the utility of nanoprobiotics in the 
delivery of encapsulated bacteria is being carried out. For encapsulation of probiotic have been used 
mainly nanoparticles i.e., with of selenium and gold particles of a size in the range 10–1000 nm; 
nanolayers, consisting of at least three layers of a charged polyelectrolyte, a polymeric layer, and a 
functionalized polysaccharide or polyether; nanoemulsions consisting of a liquid phase dispersion in 
another liquid phase with droplet size less 200 nm; nanobeads (nanosized bacteria-enabled 
autonomous delivery system) and emerging product of nanofibers [169]. The best technique for 
probiotics encapsulation was mainly chosen for protecting the cells against an adverse environment 
in the gastrointestinal tract, in order to allow their release in a viable and metabolically active state in 
the intestine [170]. 
Kazmierczak et al. [171] describe an innovative engineering approach to load such nanoparticles 
onto a biological “mailman” (a novel, nontoxic, therapeutic strain of Salmonella typhimurium 
engineered to preferentially and precisely seek out, penetrate, and hinder prostate cancer cells as 
biological delivery system) that will deliver the therapeutics to a target site. Another example of 
probiotic bacteria encapsulated with nanoparticles was given by Hu et al. [172] that showed how 
coating live bacterial cells with synthetic nanoparticles represents a promising strategy to engineer 
efficient and versatile DNA vaccines. Feher et al. [173] have reported the use of nano-sized particles 
of probiotics for preventing and treating neuroinflammation. 
Probiotics are indeed receiving special interest as an alternative to the classical antibiotics to 
overcome bacterial resistance. As prebiotics enhance the activity of probiotics, Kim et al. [162] 
proposed the development of a prebiotic formulation composed of Pediococcus acidilactidi loaded in 
phthalyl dextran nanoparticles by conjugating phthalic anhydride with dextran [162]. The authors 
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evaluated the cellular effects of the produced nanomaterial and checked the antimicrobial properties 
of the probiotics. The loading of P. acidilactidi into phthalyl dextran nanoparticles was found to 
enhance the production of antimicrobial peptides by probiotics by a self-defense mechanism, with 
improved antimicrobial effect against Gram (+) and Gram (−) micro-organisms compared to the 
probiotics alone. The same authors previously reported that prebiotic phthalyl inulin nanoparticles 
could also enhance the antimicrobial activities of P. acidilactici [174]. 
Hong et al. also reported the enhanced antimicrobial activity of phthalyl pullulan nanoparticles 
treated with L. plantarum against Escherichia coli K99 and Listeria monocytogenes [164]. The 
nanoparticles were internalized into the L. plantarum by an energy-dependent and galactose 
transporter-dependent mechanism and a higher amount of plantaricin, a natural antibacterial 
peptide, was secreted from the developed nanoprobiotic than from probiotic alone.  
The use of spores from probiotics have been recently proposed as a delivery system for 
chemotherapeutic drugs. Song et al. [175] produced deoxycholic acid-modified spores to be loaded 
with doxorubicin and sorafenib as an approach for autonomous production of nanoparticles in the 
gastrointestinal tract. Such approach envisions drug protection upon oral administration to improve 
bioavailability. Besides, the release is based on the disintegrated hydrophobic protein and the 
hydrophilic deoxycholic acid with enhanced uptake by the epithelial cells via the bile acid pathway, 
increasing basolateral drug release.  
The anticancer activity of silver/Lactobacillus rhamnosus GG nanoparticles was described by Aziz 
et al. [155]. Using the MTT assay, the authors demonstrated that the viability of HT-29 cell lines has 
been significantly reduced when applying the highest tested nanoparticle concentration, leading to 
apoptosis. The method of synthesizing silver/Lactobacillus rhamnosus GG nanoparticles was also 
found to be cost-effective, offering a viable nanoprobiotic approach for biomedical applications.  
It is worth mentioning the work of Fung et al. [176] where, by investigating the agrowaste-based 
nanofibers as a probiotic encapsulant, has proposed the use of nanofibers for the nanoencapsulation 
of L. acidophilus using 8% poly(vinyl alcohol) to produce nanofibers by electrospinning technology. 
The authors suggested how thermal behavior of nanofibers suggested possible thermal protection of 
probiotics in heat-processed foods. Nagy et al. [177] by investigating the suitability of electrospinning 
for biodrugs delivery to produce vaginal drug delivery systems, concluded how nanofibers can 
provide long term stability for huge amounts of living bacteria if they are kept at (or below) 7 °C. The 
recent work of Zupancic et al. [178], who studied the incorporation of a range of safe lactic acid 
bacteria into poly(ethylene oxide)-based nanofibers, evidenced that all of the lactic acid bacteria were 
viable after incorporation into nanofibers, with 0–3 log CFU/mg loss in viability, depending on the 
species. Moreover, the authors reported that viability can be correlated with the hydrophobicity and 
to the extreme length of lactic acid bacteria, whereas a horizontal or vertical electrospinning set-up 
did not have any role. Development of nanofibers via electrospinning has a great potential and use 
in pharmaceutical and food industry for their properties i.e., sterile nature, biocompatibility, 
adhesiveness, efficiency, and as vehicle for controlled and sustained release in drug delivery [179–
182]. Electrospinning and electrospraying represent innovative technologies for the delivery of 
nutraceuticals [183]. 
An example of nanolayers coated probiotics has been given by Franz et al. [184] who developed 
layer-by-layer nano self-assembly coating of Allochromatium vinosum with different polyelectrolyte 
combinations and investigated substrate uptake in bacteria: surface charge neither affected sulfide 
uptake nor the contact formation between the cells and solid sulfur, whereas increasing layers slowed 
or inhibited the uptake of sulfide and elemental sulfur. 
The recent work of Ebrahimnejad et al. [185] described the use of chitosan for nanoencapsulation 
of L. acidophilus as probiotic bacteria, by concluding how nanoencapsulation of probiotic bacteria 
represents a promising strategy in enhancing the viability and survival of them against gastro-
intestinal environmental conditions. 
Ranjan et al. [186] reported physicochemical characterization and potential prebiotic effect of 
whey protein isolate/inulin nano complex. 
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Atia et al. [167] developed an encapsulated oral-symbiotic supplement by studying the effect of 
adding inulin in alginate beads and observed their ability to protect three probiotic strains, namely, 
P. acidilactici, L. reuteri, and L. salivarius. The antimicrobial and probiotic properties of bacterial strains 
were found not to be affected by the encapsulation. 
Krithika and Preetha [166] have developed a protein-based inulin incorporated symbiotic 
nanoemulsion for enhanced stability of probiotic; whey protein concentrate/inulin nano complex can 
be recommended as a delivery system for various probiotics in food products. 
Salmerón et al. [187] reported the development fermented beverages with synbiotic properties, 
and the incorporation of nanoparticles with unique and specific bioactivity, to improve organoleptic 
characteristics, absorption, and delivery of nutrients and bioactive compounds which has opened a 
new horizon in this segment of food created to improve human health and well-being. 
Formulation of protein-based inulin incorporated synbiotic nanoemulsion for enhanced stability 
of probiotic are currently studied extensively. 
It is worth mentioning the work of Rezaee et al. [188] that investigated the antimicrobial activity 
of Ag and TiO2 nano-particles on three species of Lactobacillus i.e., L. casei ATCC 39392, L. plantarum 
ATCC 8014, and L. fermentum ATCC 9338 in the presence and absence of raffinose, lactulose, and 
inulin, respectively. The results indicated that silver nanoparticles decreased 85%, 85%, and 71% of 
L. casei, L. plantarum, and L. fermentum, respectively, after 48 h and decreased percentages of L. casei, 
L. plantarum, and L. fermentum that were 16%, 64%, and 4% in the presence of the prebiotics. Nano 
TiO2 particles decreased 59%, 85%, and 61% of L. casei, L. plantarum, and L. fermentum, respectively, 
after 48 h, and decreased percentages of L. casei, L. plantarum, and L. fermentum which were 16%, 2%, 
and 4% in the presence of these prebiotics. 
The treatment of gastrointestinal disorders (e.g., diarrhea) using nanoprobiotics is also a 
relatively unexplored field. Khan et al. [189] aimed at quantifying the concentration of nanomaterials 
commercialized in chocolates and evaluated their effect on a commercial probiotic formulation 
(containing Bacillus coagulans, Enterococcus faecalis, and Enterococcus faecium) usually used to treat 
diarrhea in children [189]. The known probiotic activities, such as acid production, biofilm formation, 
growth, and antibiotic resistance were observed from isolated bacteria, while the isolated titanium 
oxide nanoparticles from chocolates were shown to inhibit the growth and activity of the probiotic 
formulation in a concentration range of 125–500 μg/mL in vitro [189]. The outcomes of this study 
concluded that TiO2 in chocolate discourages the survival of probiotic bacteria in the gastrointestinal 
tract.  
To trace target probiotics in situ and in real-time, Liu et al. [190] developed an in vivo probing 
strategy using persistent luminescence nanophosphors surface-modified by plasmid-like DNA as 
optical labelling and background-free fluorescence bioimaging as signal readout. The surface 
modification with DNA molecules was shown to promote the nanoparticles penetration into the 
bacteria and facilitated in vivo bioimaging. Such an approach opens new research perspectives in 
terms of food safety making use of nanotechnologies. 
3. Conclusions 
Only a few experimental studies are present in literature on nanoprebiotics and nanoprobiotics, 
while studies on this prominent issue are needed, covering effectiveness and safety aspects as it has 
been developed for pharmaceuticals. The potential of nanotechnologies in the food area is an 
emerging challenge as well as the nanonutraceuticals, which are an emerging field of study in the 
nutraceuticals area. Safety and regulatory aspects should be considered to depict the potentiality of 
nanoprobiotics and nanoprebiotics. Nanoformulation should be accompanied with regulatory 
requirements to ensure efficacy, safety, and authorization procedures. As a general guideline, the 
European Authority for Food Safety (EFSA) [191] has developed an approach for assessing the 
potential risks arising from the applications of nanoscience and nanotechnologies in the food and 
feed chain. Regarding prebiotics and probiotics, McClements and Xiao [192] developed a summary 
of the possible applications of inorganic and organic nanoparticles in foods, a description of the 
nanoparticle characteristics, and discussed the importance of the food matrix and gastrointestinal 
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tract effects on nanoparticle properties as well as potential possible toxicity mechanisms of different 
food-grade nanoparticles. The same authors concluded, however, that many of these nanoparticles 
are unlikely to have adverse-side effects on human health in line with previously reported data [193]. 
Nonetheless, in order to assess the effective use of food-grade nanoparticles, further studies are 
expected to exploit and assess safety, improved bioavailability, and efficacy.  
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